Upadacitinib for preventing eye inflammation in back arthritis patients
Treatments studied
Part of Bones, joints & muscles, Eyes & vision clinical trials.
This study tests if upadacitinib can reduce episodes of eye inflammation (uveitis) in people with axial spondyloarthritis (a type of inflammatory back arthritis). You may qualify if you've had at least one uveitis flare in the past year and your arthritis is still active despite standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have axial spondyloarthritis (a chronic inflammatory condition of your spine and joints) diagnosed by your rheumatologist.
- You have had at least one episode of acute anterior uveitis (eye inflammation) in the past year, confirmed by an eye doctor.
- Your arthritis is moderately to severely active (scores of 4 or higher on a pain and stiffness scale).
- You have tried at least two different NSAIDs (like ibuprofen or naproxen) for at least 4 weeks total without enough relief, or you cannot take NSAIDs due to side effects.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well different newer medications work for people with axial spondyloarthritis or psoriatic arthritis. It focuses on those just starting treatment with bimekizumab, risankizumab, guselkumab, upadacitinib, or a TNF inhibitor.
This study tests how well upadacitinib (a pill taken daily) works for people with active psoriatic arthritis that also affects the spine. It is for those who have not responded well enough to other treatments like NSAIDs or biologics.
This study tests whether the medication upadacitinib (Rinvoq) works similarly for psoriatic arthritis and rheumatoid arthritis. Participants will have ultrasound imaging to track joint inflammation while taking upadacitinib.
This study tests if the medication upadacitinib can help people whose eyelid rash has not improved with prescription creams. It's for adults who have had eyelid dermatitis for at least two months and have tried at least one prescribed cream that didn't work.
This trial compares two newer medications for people with axial spondyloarthritis who have already tried a TNF inhibitor (a type of biologic) without success. The goal is to see which one works better at reducing symptoms like pain and stiffness.
This study looks at how well upadacitinib treats enthesitis (pain where tendons or ligaments attach to bone) in people with psoriatic arthritis. Researchers will use ultrasound to measure improvement. The trial is for adults who have already tried at least one biologic drug, including an anti-TNF, without success.
Hear when a new Axial Spondylarthritis (axSpA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.